Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACOG Alpha Cognition	$9.35 +2.9%	$9.70	$3.75 ▼ $11.54	$145.62M	2.72	44,723 shs	33,315 shs
BCYC Bicycle Therapeutics	$7.56 -3.8%	$8.00	$6.10 ▼ $28.67	$544.34M	1.44	277,051 shs	173,384 shs
EOLS Evolus	$6.37 -28.5%	$9.38	$5.85 ▼ $17.82	$574.48M	1.12	1.19 million shs	13.69 million shs
ZVRA Zevra Therapeutics	$11.48 +0.3%	$10.28	$6.19 ▼ $13.16	$625.53M	1.87	1.14 million shs	690,666 shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACOG Alpha Cognition	+2.86%	+0.75%	-16.81%	+26.35%	+934,999,900.00%
BCYC Bicycle Therapeutics	-3.82%	-11.16%	+5.44%	-7.67%	-68.99%
EOLS Evolus	-28.51%	-28.91%	-30.31%	-36.87%	-50.73%
ZVRA Zevra Therapeutics	+0.35%	+4.46%	+1.86%	+47.37%	+45.69%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ACOG Alpha Cognition	1.6763 of 5 stars	3.5	0.0	0.0	2.3	0.8	0.0
BCYC Bicycle Therapeutics	3.655 of 5 stars	3.4	4.0	0.0	3.4	4.2	0.6
EOLS Evolus	3.4624 of 5 stars	3.4	0.0	3.5	0.8	3.3	0.6
ZVRA Zevra Therapeutics	2.0787 of 5 stars	3.6	1.0	0.0	3.8	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACOG Alpha Cognition	3.00	Buy	$20.00	113.90% Upside
BCYC Bicycle Therapeutics	2.67	Moderate Buy	$21.25	181.08% Upside
EOLS Evolus	2.80	Moderate Buy	$21.25	233.59% Upside
ZVRA Zevra Therapeutics	3.11	Buy	$23.71	106.57% Upside

Current Analyst Ratings Breakdown

Latest ACOG, EOLS, ZVRA, and BCYC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/6/2025	EOLS Evolus	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$21.00 ➝ $18.00
8/6/2025	EOLS Evolus	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$27.00 ➝ $20.00
8/6/2025	EOLS Evolus	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold	$22.00
7/17/2025	BCYC Bicycle Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$32.00 ➝ $25.00
7/10/2025	ZVRA Zevra Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$25.00 ➝ $29.00
7/2/2025	ZVRA Zevra Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$26.00
5/16/2025	ACOG Alpha Cognition	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00 ➝ $20.00
5/14/2025	ZVRA Zevra Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
5/14/2025	ZVRA Zevra Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$25.00 ➝ $25.00
5/8/2025	EOLS Evolus	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$22.00 ➝ $22.00

(Data available from 8/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACOG Alpha Cognition	N/A	N/A	N/A	N/A	$2.59 per share	N/A
BCYC Bicycle Therapeutics	$25.72M	20.35	N/A	N/A	$11.48 per share	0.66
EOLS Evolus	$266.27M	1.54	N/A	N/A	$0.09 per share	70.78
ZVRA Zevra Therapeutics	$23.61M	26.59	N/A	N/A	$0.74 per share	15.51

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACOG Alpha Cognition	-$14.64M	-$1.20	N/A	∞	N/A	N/A	-65.83%	-48.21%	8/14/2025 (Confirmed)
BCYC Bicycle Therapeutics	-$169.03M	-$3.14	N/A	N/A	N/A	-790.07%	-25.54%	-21.23%	N/A
EOLS Evolus	-$50.42M	-$0.98	N/A	N/A	N/A	-22.31%	-3,474.21%	-24.73%	N/A
ZVRA Zevra Therapeutics	-$105.51M	-$1.90	N/A	57.40	N/A	-226.78%	-201.05%	-53.55%	8/12/2025 (Estimated)

Latest ACOG, EOLS, ZVRA, and BCYC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	ACOG Alpha Cognition	-$0.84	N/A	N/A	N/A	$2.32 million	N/A
8/12/2025	Q2 2025	ZVRA Zevra Therapeutics	$0.65	N/A	N/A	N/A	$22.49 million	N/A
5/15/2025	Q1 2025	ACOG Alpha Cognition	-$0.58	-$0.20	+$0.38	-$0.13	$0.50 million	$2.93 million
5/13/2025	Q1 2025	ZVRA Zevra Therapeutics	-$0.21	-$0.06	+$0.15	-$0.06	$16.96 million	$20.40 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACOG Alpha Cognition	N/A	N/A	N/A	N/A	N/A
BCYC Bicycle Therapeutics	N/A	N/A	N/A	N/A	N/A
EOLS Evolus	N/A	N/A	N/A	N/A	N/A
ZVRA Zevra Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACOG Alpha Cognition	N/A	17.14	16.83
BCYC Bicycle Therapeutics	N/A	14.86	14.86
EOLS Evolus	22.00	2.34	2.16
ZVRA Zevra Therapeutics	1.46	3.02	2.93

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACOG Alpha Cognition	N/A
BCYC Bicycle Therapeutics	86.15%
EOLS Evolus	90.69%
ZVRA Zevra Therapeutics	35.03%

Insider Ownership

Company	Insider Ownership
ACOG Alpha Cognition	14.00%
BCYC Bicycle Therapeutics	22.90%
EOLS Evolus	5.90%
ZVRA Zevra Therapeutics	2.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACOG Alpha Cognition	N/A	16.02 million	13.78 million	N/A
BCYC Bicycle Therapeutics	240	69.25 million	53.40 million	Optionable
EOLS Evolus	170	64.48 million	60.67 million	Optionable
ZVRA Zevra Therapeutics	20	54.68 million	53.37 million	Optionable

ACOG, EOLS, ZVRA, and BCYC Headlines

Recent News About These Companies

Zevra Therapeutics (ZVRA) to Release Quarterly Earnings on Tuesday

August 6 at 12:26 PM | marketbeat.com

Zevra Therapeutics (ZVRA) Reports Next Week: Wall Street Expects Earnings Growth

August 5 at 11:01 AM | zacks.com

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Short Interest Up 166.3% in July

August 5 at 2:21 AM | americanbankingnews.com

Zevra Therapeutics Announces Details for Q2 2025 Financial Results Call

August 4 at 7:30 AM | globenewswire.com

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Short Interest Update

August 4 at 2:58 AM | marketbeat.com

What is William Blair's Estimate for ZVRA Q3 Earnings?

August 1, 2025 | marketbeat.com

Equities Analysts Set Expectations for ZVRA FY2025 Earnings

August 1, 2025 | americanbankingnews.com

Q3 Earnings Forecast for ZVRA Issued By William Blair

August 1, 2025 | americanbankingnews.com

Does Zevra Therapeutics (ZVRA) Have the Potential to Rally 117.11% as Wall Street Analysts Expect?

July 31, 2025 | zacks.com

What is William Blair's Estimate for ZVRA FY2025 Earnings?

July 31, 2025 | marketbeat.com

Zevra Therapeutics Submits Marketing Authorization Application to European Medicines Agency to Review Arimoclomol for the Treatment of Niemann-Pick Disease Type C

July 28, 2025 | globenewswire.com

Readystate Asset Management LP Purchases 616,370 Shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA)

July 23, 2025 | marketbeat.com

AIGH Capital Management LLC Has $10.77 Million Stock Position in Zevra Therapeutics, Inc. (NASDAQ:ZVRA)

July 22, 2025 | marketbeat.com

Zevra Therapeutics (NASDAQ:ZVRA) Downgraded to Buy Rating by Wall Street Zen

July 20, 2025 | marketbeat.com

Zevra Therapeutics Announces MIPLYFFA® and OLPRUVA® Presentations at the Annual Meeting of the Southeastern Regional Genetics Group (SERGG)

July 18, 2025 | globenewswire.com

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Shares Acquired by Mystic Asset Management Inc.

July 17, 2025 | marketbeat.com

Zevra Therapeutics Announces Open Label Extension Data Showing Sustained Long-Term Efficacy of MIPLYFFA for the Treatment of NPC Published in the Journal of Molecular Genetics ...

July 16, 2025 | finanznachrichten.de

Are You Looking for a Top Momentum Pick? Why Zevra Therapeutics (ZVRA) is a Great Choice

July 16, 2025 | zacks.com

5 Small Drug Stocks to Buy Amid Trump's New Tariff Threats

July 16, 2025 | zacks.com

Zevra Therapeutics Announces Open Label Extension Data Showing Sustained Long-Term Efficacy of MIPLYFFA for the Treatment of NPC Published in the Journal of Molecular Genetics and Metabolism

July 16, 2025 | globenewswire.com

Zevra Therapeutics Publishes Long-Term Efficacy and Safety Results for MIPLYFFA in Niemann-Pick Disease Type C

July 16, 2025 | quiverquant.comQ

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACOG, EOLS, ZVRA, and BCYC Company Descriptions

Alpha Cognition NASDAQ:ACOG

$9.35 +0.26 (+2.86%)

As of 08/6/2025 04:00 PM Eastern

Alpha Cognition, Inc. is a clinical stage biopharmaceutical company that develops treatments for underserved neurodegenerative diseases such as Alzheimer's Dementia and Amyotrophic Lateral Sclerosis. The company was founded in 2000 and is headquartered in Vancouver, Canada.

Bicycle Therapeutics NASDAQ:BCYC

$7.56 -0.30 (-3.82%)

Closing price 08/6/2025 04:00 PM Eastern

Extended Trading

$7.52 -0.03 (-0.46%)

As of 08/6/2025 05:34 PM Eastern

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial. The company also developing BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease; and BT7401, a multivalent bicycle CD137 agonist which is in phase IIa to treat advanced solid tumors. In addition, it develops Novel anti-infective, which is in preclinical trial targeting anti-infectives disease; CNS targets, which is in preclinical trial targeting CNS disease; and Novel neuromuscular targets, which is in preclinical trial targeting neuromuscular disease. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas. It has collaboration and license agreement with Bayer Consumer Care AG; Novartis Pharma AG; Cancer Research UK; Cancer Research Technology Ltd; and Oxurion NV. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.

Evolus NASDAQ:EOLS

$6.37 -2.54 (-28.51%)

Closing price 08/6/2025 04:00 PM Eastern

Extended Trading

$6.25 -0.12 (-1.95%)

As of 08/6/2025 07:55 PM Eastern

Evolus, Inc., a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. It also provides dermal filler products under the Estyme and Evolysse names. The company was incorporated in 2012 and is headquartered in Newport Beach, California.

Zevra Therapeutics NASDAQ:ZVRA

$11.48 +0.04 (+0.35%)

Closing price 08/6/2025 04:00 PM Eastern

Extended Trading

$11.40 -0.09 (-0.74%)

As of 08/6/2025 07:59 PM Eastern

Zevra Therapeutics, Inc. discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome. In addition, it offers AZSTARYS, a once-daily treatment for attention deficit hyperactivity disorder in patients aged six years and older; OLPRUVA to treat urea cycle disorders; and Arimoclomol for the treatment of niemann pick disease type C, an ultra-rare neurodegenerative lysosomal storage disorder. The company has collaboration and license agreement with Commave Therapeutics SA to develop, manufacture and commercialize the company's product candidates containing SDX and d-methylphenidate; and license agreement with Acer and Relief Therapeutics, Inc. to develop and commercialize rights for OLPRUVA. The company was formerly known as KemPharm, Inc. and changed its name to Zevra Therapeutics, Inc. in February 2023. Zevra Therapeutics, Inc. was incorporated in 2006 and is headquartered in Celebration, Florida.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time